CTRI/2022/05/042515已完成未知
A Prospective,Randomized,Two-arm,Open label study to evaluate Efficacy ofCamel Milk Powder Formulation in height growth, immunity and gut health Improvement inchildren between 05 to 16 years of Age
Aadvik Foods Products Pvt Ltd0 个研究点目标入组 51 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 51
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Children of either gender between 5 to 16 Years of age.
- •2) Children of height less than 97 percentile as per the Indian Academy
- •of Paediatrics (IAP) growth charts, 2015.
- •3) Children (if applicable) and their parents who can understand and are
- •willing to provide the appropriate consent.
排除标准
- •1) Children diagnosed with growth disorders like Marasmus and
- •kwashiorkor.
- •2) Children currently suffering from abdominal pain and intestinal
- •discomfort accompanied by vomiting and diarrhoea at the time of
- •3) Children suffering from any chronic diseases or any diagnosis, as per
- •the discretion of the investigator, which may jeopardize the study
- •assessments or outcome.
研究者
相似试验
已完成
不适用
Clinical trial study to investigate safety and efficacy of ImmunoSEB and ProbioSEBCTRI/2020/08/027168SRV Hospital60
已完成
不适用
Clinical Study to Investigate Safety and Efficacy of ImmunoSEB and ProbioSEBCTRI/2020/09/027685Chirayu Medical College and Hospital40
已完成
4 期
A randomized open label, compared study to evaluate safety and efficacy of a New antimicrobial wound dressing (VELVERT) with a Standard dressing (SD) in patients with infected wound.CTRI/2021/12/038436Datt Mediproduct Pvt Ltd70
进行中（未招募）
1 期
Pozelimab and Cemdisiran Combination Treatment in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab MonotherapyParoxysmal Nocturnal HemoglobinuriaMedDRA version: 21.1Level: LLTClassification code 10055629Term: Paroxysmal nocturnal hemoglobinuriaSystem Organ Class: 100000004857EUCTR2020-005005-17-HURegeneron Pharmaceuticals, Inc.24
尚未招募
2 期
An open-label randomized comparative trial of blinatumomab for B-cell acute lymphoblastic leukemiaB-precursor AJPRN-jRCT2031230581Kato Motohiro180